Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting

BACKGROUND: The TROIKA trial established that HD201 and trastuzumab were equivalent in terms of primary endpoints (total pathological complete response) following neoadjuvant treatment. The objective of the present analysis was to compare survival outcomes and final safety. METHODS: In the TROIKA tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivot, Xavier, Manikhas, Alexey Georgievitch, Shamrai, Volodymyr, Dzagnidze, Giorgi, Soo Hoo, Hwoei Fen, Kaewkangsadan, Viriya, Petrelli, Fausto, Villanueva, Cristian, Kim, Jamie, Pradhan, Sumita, Jaison, Litha, Feyaerts, Peggy, Kaufman, Leonard, Derde, Marie-Paule, Deforce, Filip, Cox, David G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890819/
https://www.ncbi.nlm.nih.gov/pubmed/36721174
http://dx.doi.org/10.1186/s12885-023-10574-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890819/
https://www.ncbi.nlm.nih.gov/pubmed/36721174
http://dx.doi.org/10.1186/s12885-023-10574-2

Ejemplares similares